Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice

Molecular Therapy

Volumn 18, Issue 1, 2010, Pages 161-170

  Beer, Shelly ^a   Bellovin, David I ^a   Lee, Joyce S ^b   Komatsubara, Kimberly ^a   Wang, Lora S ^b   Koh, Huishan ^a   Börner, Kathleen ^c   Storm, Theresa A ^b   Davis, Corrine R ^b   Kay, Mark A ^b   Felsher, Dean W ^a   Grimm, Dirk ^b,c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; MICRORNA; MYC PROTEIN; PARVOVIRUS VECTOR; PROTEIN P53; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER TOXICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; ONCOGENE; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CARCINOMA, HEPATOCELLULAR; GENES, MYC; GENETIC VECTORS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

MUS; MUS MUSCULUS;

EID: 74149092180     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.222     Document Type: Article

References (50)

1. Calvisi, DF and Thorgeirsson, SS (2005). Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol 33: 181-184.
2. Thorgeirsson, SS and Grisham, JW (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346.
3. Dang, CV (1999). c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1-11.
4. Felsher, DW and Bishop, JM (1999). Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA 96: 3940-3944.
5. Grandori, C, Cowley, SM, James, LP and Eisenman, RN (2000). The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699.
6. Oster, SK, Ho, CS, Soucie, EL and Penn, LZ (2002). The myc oncogene: MarvelouslY Complex. Adv Cancer Res 84: 81-154.
7. Pelengaris, S, Khan, M and Evan, G (2002). c-MYC: more than just a matter of life and death. Nat Rev Cancer 2: 764-776.
8. Beer, S, Zetterberg, A, Ihrie, RA, McTaggart, RA, Yang, Q, Bradon, N et al. (2004). Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2: e332.
9. Felsher, DW and Bishop, JM (1999). Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199-207.
10. Kistner, A, Gossen, M, Zimmermann, F, Jerecic, J, Ullmer, C, Lübbert, H et al. (1996). Doxycycline-mediated quantitative and tissue-specifc control of gene expression in transgenic mice. Proc Natl Acad Sci USA 93: 10933-10938.
11. Shachaf, CM, Kopelman, AM, Arvanitis, C, Karlsson, A, Beer, S, Mandl, S et al. (2004). MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117.
12. Felsher, DW (2004). Putting oncogenes into a developmental context. Cancer Biol Ther 3: 942-944.
13. Grimm, D and Kay, MA (2003). From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3: 281-304.
14. Grimm, D and Kay, MA (2006). Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 13: 563-575.
15. Grimm, D, Pandey, K and Kay, MA (2005). Adeno-associated virus vectors for short hairpin RNA expression. Meth Enzymol 392: 381-405.
16. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541.
17. McCarty, DM, Monahan, PE and Samulski, RJ (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote effcient transduction independently of DNA synthesis. Gene Ther 8: 1248-1254.
18. Nakai, H, Fuess, S, Storm, TA, Muramatsu, S, Nara, Y and Kay, MA (2005). Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 79: 214-224.
19. Nakai, H, Yant, SR, Storm, TA, Fuess, S, Meuse, L and Kay, MA (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75: 6969-6976.
20. Giering, JC, Grimm, D, Storm, TA and Kay, MA (2008). Expression of shRNA from a tissue-specifc pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 16: 1630-1636.
21. Doege, H, Grimm, D, Falcon, A, Tsang, B, Storm, TA, Xu, H et al. (2008). Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem 283: 22186-22192.
22. Amati, B, Alevizopoulos, K and Vlach, J (1998). Myc and the cell cycle. Front Biosci 3: d250-d268.
23. Hermeking, H, Rago, C, Schuhmacher, M, Li, Q, Barrett, JF, Obaya, AJ et al. (2000). Identifcation of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA 97: 2229-2234.
24. Menssen, A and Hermeking, H (2002). Characterization of the c-MYC-regulated transcriptome by SAGE: identifcation and analysis of c-MYC target genes. Proc Natl Acad Sci USA 99: 6274-6279.
25. Obaya, AJ, Mateyak, MK and Sedivy, JM (1999). Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene 18: 2934-2941.
26. Yin, XY, Grove, L, Datta, NS, Katula, K, Long, MW and Prochownik, EV (2001). Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res 61: 6487-6493.
27. Cole, MD and Cowling, VH (2008). Transcription-independent functions of MYC: regulation of translation and DNA replication. Nat Rev Mol Cell Biol 9: 810-815.
28. Gomez-Roman, N, Grandori, C, Eisenman, RN and White, RJ (2003). Direct activation of RNA polymerase III transcription by c-Myc. Nature 421: 290-294.
29. Johnson, SA, Dubeau, L and Johnson, DL (2008). Enhanced RNA polymerase III-dependent transcription is required for oncogenic transformation. J Biol Chem 283: 19184-19191.
30. Kenneth, NS, Ramsbottom, BA, Gomez-Roman, N, Marshall, L, Cole, PA and White, RJ (2007). TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. Proc Natl Acad Sci USA 104: 14917-14922.
31. Kaplowitz, N (2002). Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 22: 137-144.
32. Plaa, GL (2000). Chlorinated methanes and liver injury: highlights of the past 50 years. Annu Rev Pharmacol Toxicol 40: 42-65.
33. Recknagel, RO, Glende, EA Jr, Dolak, JA and Waller, RL (1989). Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther 43: 139-154.
34. Chisari, FV (1995). Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 22(4 Pt 1): 1316-1325.
35. Chisari, F V, Klopchin, K, Moriyama, T, Pasquinelli, C, Dunsford, HA, Sell, S et al. (1989). Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59: 1145-1156.
36. Dunsford, HA, Sell, S and Chisari, FV (1990). Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 50: 3400-3407.
37. Fan, CY, Pan, J, Usuda, N, Yeldandi, AV, Rao, MS and Reddy, JK (1998). Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor α natural ligand metabolism. J Biol Chem 273: 15639-15645.
38. Fausto, N (1999). Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis 19: 243-252.
39. Mauad, TH, van Nieuwkerk, CM, Dingemans, KP, Smit, JJ, Schinkel, AH, Notenboom, RG et al. (1994). Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative infammatory cholangitis and hepatocarcinogenesis. Am J Pathol 145: 1237-1245.
40. Smit, JJ, Schinkel, AH, Oude Elferink, RP, Groen, AK, Wagenaar, E, van Deemter, L et al. (1993). Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451-462.
41. Sanders, S and Thorgeirsson, SS (1999). Phenobarbital promotes liver growth in c-myc/TGF-α transgenic mice by inducing hypertrophy and inhibiting apoptosis. Carcinogenesis 20: 41-49.
42. Sanders, S and Thorgeirsson, SS (2000). Promotion of hepatocarcinogenesis by phenobarbital in c-myc/TGF-α transgenic mice. Mol Carcinog 28: 168-173.
43. Chang, TC, Yu, D, Lee, YS, Wentzel, EA, Arking, DE, West, KM et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50.
44. Kota, J, Chivukula, RR, O'Donnell, KA, Wentzel, EA, Montgomery, CL, Hwang, HW et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
45. Sell, S (2001). Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology 33: 738-750.
46. Calin, GA and Croce, CM (2006). MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394.
47. Snøve, O Jr and Rossi, JJ (2006). Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi. Genome Biol 7: 231.
48. Snøve, O Jr and Rossi, JJ (2006). Expressing short hairpin RNAs in vivo. Nat Methods 3: 689-695.
49. Grimm, D, Lee, JS, Wang, L, Desai, T, Akache, B, Storm, TA et al. (2008). In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 82: 5887-5911.
50. Zolotukhin, S, Potter, M, Hauswirth, WW, Guy, J and Muzyczka, N (1996). A "humanized" green fuorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70: 4646-4654.